Full-Time
UX Designer 1
Digital Services
Posted on 8/11/2026
Aflac
10,001+ employees
Supplemental health and life insurance provider
Compensation Overview
$75k - $95k/yr
Remote in USA + 1 more
More locations: Georgia, USA
Remote
Remote within the continental United States; occasional office visits may be requested in advance.
Bachelor's
 UI/UX & Design (1) |
|---|
Get referred to Aflac
See people who can refer or advise you
- A bachelor's degree in Design, Marketing, Computer Science, or another related field, or an equivalent combination of education and experience.
- Zero to two or more years of related work experience in UX design.
- Familiarity with fundamental design principles, including color theory, typography, and layout.
- Basic proficiency in design tools such as Sketch, Figma, Adobe XD, or similar tools.
- Understanding of basic user research methods, including surveys, interviews, and usability testing.
- Ability to create simple user personas and user journey maps.
- Experience creating low-fidelity wireframes and basic interactive prototypes.
- Understanding of the role of wireframes and prototypes in the design process.
- Ability to communicate design decisions and present work.
- Assist, as part of a team, with designing user interfaces or page elements that align with brand and digital design standards.
- Deliver sketches, design comps, wireframes, user flows, and prototypes showing how users experience the product, service, or application.
- Conduct market or competitive analysis and other user research as needed.
- Use personas, journey maps, and other artifacts to inform design solutions.
- Assist with experience design activities using appropriate tools, methods, and processes.
- Assist in evaluating digital designs and apply design, branding, and accessibility guidelines.
- Ideate and test design concepts and solutions to reduce risks and understand desirability and usability.
- Support the UX practice and handle updates to the design system and content management system as needed.
- Perform other duties as needed.
- Experience with artificial intelligence tools such as Claude, Copilot, and ChatGPT.
Aflac provides supplemental health and life insurance products to individuals and families, operating mainly in two regions: Aflac Japan and Aflac U.S. Its policies are designed to cover out-of-pocket costs from health events and income loss, including cancer, critical illness, accidents, hospital stays, and life events. These benefits are paid directly to policyholders to help manage medical expenses not fully covered by primary insurance. The products are distributed through a network of independent agents, brokers, and financial advisors, enabling a high-volume, low-premium model that supports a large, stable customer base and ongoing revenue. Japan is its largest market, and the company uses this broad distribution and scale to differentiate itself from competitors. The goal is to provide straightforward financial protection against unexpected health-related costs while expanding its presence in the U.S. and Japanese markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
Columbus, Georgia
Founded
1955
Get referred to Aflac
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 U.S. sales rose 2.6%, led by group voluntary and dental coverage.
- Aflac returned $1.3 billion in Q2 2026, reinforcing dividend and buyback credibility.
- Japan pretax margin reached 34.3% in Q2 2026, supporting ROE expansion.
What critics are saying
- Q2 2026 Japan sales fell 5.6%, exposing dependence on product launch timing.
- Persistency slipped to 92.7% in Q2 2026, hurting earned premiums and growth.
- If Japan lapses, FX pressure, and slower U.S. growth persist, valuation stalls.
What makes Aflac unique
- Aflac Japan keeps leading cancer and medical policies in force in 2026.
- Aflac’s 2026 product refresh, Miraito, Tsumitasu, and Anshin Palette, expands cross-selling.
- Aflac’s 2026 capital flexibility includes a shelf registration and regular yen funding.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Hybrid Work Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%Aflac's second quarter results disappointed investors despite meeting Wall Street expectations, with revenue declining 6.9% year-on-year to $4.22 billion. The insurance giant attributed the sales drop largely to difficult comparisons following last year's launch of its Miraito cancer insurance product in Japan. Chief Executive Daniel Amos said new Japanese offerings like Tsumitasu and Anshin Palette generated solid growth. US sales grew modestly, supported by group voluntary products and network dental and vision offerings. During the earnings call, analysts pressed management on several key issues. Questions focused on the sustainability of asset repositioning efforts, appetite for larger acquisitions, sequential declines in Japanese medical sales, and the impact of inflation on policy lapse rates. Amos said Aflac remains open to strategic acquisitions but will maintain discipline, favouring smaller deals that fit operationally and financially.
Aflac reported second-quarter revenue of $4.22 billion, meeting Wall Street expectations but declining 6.9% year on year. Adjusted earnings per share of $1.75 also met analyst estimates. The supplemental insurance provider attributed the revenue decline to tough comparisons in Japan following last year's cancer insurance product launch and shifting consumer preferences. However, CEO Daniel Amos highlighted solid growth from new offerings including Tsumitasu and Anshin Palette. In the US, group voluntary products and network dental and vision sales showed strength, with dental and vision product sales rising 47%. The company maintained expense discipline despite inflationary pressures. Looking ahead, Aflac plans to focus on product innovation in Japan, continued US group product momentum, and enhanced capital management. Management emphasised its commitment to dividend growth and share repurchases.
Aflac reported second-quarter revenue of $4.12 billion, missing analyst estimates of $4.23 billion and marking a 9.2% year-on-year decline. The supplemental insurance provider's adjusted earnings per share of $1.75 met expectations. The company's book value per share reached $60.35, beating estimates by 9.3% and showing 18.7% year-on-year growth. Pre-tax profit was $995 million, with a 24.2% margin. Chairman and CEO Daniel P. Amos highlighted solid earnings execution and new opportunities in Japan through products including Anshin Palette medical insurance and Miraito cancer insurance. In the US, Aflac is focusing on supplemental health products for employers. Over the past five years, Aflac's revenue has declined at a 5.1% annual rate, reflecting ongoing demand challenges.
Aflac Incorporated reported second quarter 2026 results with net earnings of $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago. Total revenues decreased 1.0% to $4.1 billion. Adjusted earnings were $883 million, down 7.7% from $957 million in the prior year quarter. Adjusted earnings per diluted share decreased 1.7% to $1.75. The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends. Chairman and CEO Daniel Amos highlighted successful product initiatives in Japan and focus on supplemental health products in the US. The board declared a third quarter dividend of $0.61 per share, payable on 1 September 2026 to shareholders of record on 19 August 2026.
Aflac has filed an omnibus shelf registration statement covering common stock, debt securities, warrants and other instruments, whilst launching its Fit Checks cancer screening awareness campaign with fashion designer Rachel Zoe. The campaign uses QR-enabled fashion pieces to link wearable design with cancer risk education. The moves demonstrate Aflac's strategy of combining capital markets flexibility with brand-building in preventive health. However, the initiatives don't materially change near-term earnings catalysts or key risks including declining Japanese premiums, currency volatility and investment income pressure. The company's second quarter 2026 earnings release, scheduled for 6-7 August, will provide insight into whether new products and digital initiatives are improving premium trends and margins in Japan and the US, Aflac's primary markets.